October 2020, Drugs Monitor

(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure

October 31, 2020

Anakinra To Prevent Respiratory Failure In COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.28.20217455v1 In this open-label prospective trial (NCT04357366), 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels ≥6 μg/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome… Continue reading "(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure"

(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction

October 31, 2020

No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19 https://doi.org/10.1007/s42770-020-00395-x This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every… Continue reading "(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction"

(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients

October 31, 2020

Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2 https://www.medrxiv.org/content/10.1101/2020.10.27.20211433v1.full.pdf This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3/13/20 and 4/16/20, requiring mechanical ventilation. Parameters that were evaluated included age,… Continue reading "(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients"

(27 Oct 2020) Dexamethasone- associated with decreased mortality among those requiring respiratory support

October 31, 2020

Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study https://www.medrxiv.org/content/10.1101/2020.10.23.20218172v1 Among patients who required respiratory support, the end-point event of death occurred in 10 patients (15.9%) who received dexamethasone and 298 patients (26.4%)… Continue reading "(27 Oct 2020) Dexamethasone- associated with decreased mortality among those requiring respiratory support"

(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early

October 31, 2020

Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1 Randomized controlled study (NCT04591600) on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per… Continue reading "(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early"

(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality

October 31, 2020

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19 https://doi.org/10.1159/000512210 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody in Cuba. All patients had underlying medical conditions.… Continue reading "(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality"

(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males

October 31, 2020

Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series https://doi.org/10.1186/s12985-020-01428-5 In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient’s conditions. Arbidol… Continue reading "(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males"

(21 Oct 2020) Tocilizumab- not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19

October 22, 2020

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2028836 A randomized, double-blind, placebo-controlled trial ( NCT04356937) involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature… Continue reading "(21 Oct 2020) Tocilizumab- not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19"

(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes

October 22, 2020

A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1 A multicentre randomized double-blind placebo-controlled trial ( NCT04325893) evaluating hydroxychloroquine in older COVID-19 patients was conducted . Eligible patients were randomized in a 1:1 ratio to receive either 800 mg… Continue reading "(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes"

(20 Oct 2020) Methylprednisolone- significantly lower hazard of death (71%) and decreased ventilator dependence

October 22, 2020

Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia https://doi.org/10.1093/ofid/ofaa421 We conducted a multicenter observational study (NCT04323592) to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite… Continue reading "(20 Oct 2020) Methylprednisolone- significantly lower hazard of death (71%) and decreased ventilator dependence"

Month: October 2020